Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

101. High dose stimulants for attention deficit hyperactivity disorder: clinical effectiveness, safety, and guidelines

High dose stimulants for attention deficit hyperactivity disorder: clinical effectiveness, safety, and guidelines High dose stimulants for attention deficit hyperactivity disorder: clinical effectiveness, safety, and guidelines High dose stimulants for attention deficit hyperactivity disorder: clinical effectiveness, safety, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. High dose stimulants for attention deficit hyperactivity disorder: clinical effectiveness, safety, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2015 Authors' conclusions One systematic review, three randomized-controlled trials, and four non-randomized studies were identified regarding high dose stimulants for Attention Deficit Hyperactivity Disorder. Final publication URL Indexing

2015 Health Technology Assessment (HTA) Database.

102. Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder in Children

of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. Quantitative electroencephalography as a diagnostic aid for attention-deficit/hyperactivity disorder in children. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 29(1). 2014 Authors' objectives The objective of this Assessment is to evaluate the use of QEEG as a diagnostic aid to confirm a clinical diagnosis of ADHD or the need for additional testing for ADHD. Authors' conclusions Correctly (...) diagnosing ADHD is important, especially given the availability of treatment and treatment side effects. Concern has been voiced regarding possible overdiagnosis—and therefore overtreatment—of ADHD. Because the nature of the ADHD diagnosis increases the likelihood of variation across practitioners, an accurate diagnostic test for ADHD might improve health outcomes. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Attention Deficit Disorder with Hyperactivity; Childs

2015 Health Technology Assessment (HTA) Database.

103. Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder

Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) disorder Article Text Psychological interventions Group cognitive-behavioural therapy may reduce symptoms and impairment in adolescents with attention-deficit/hyperactivity disorder David Coghill Statistics from Altmetric.com ABSTRACT FROM : Vidal R, Castells J, Richarte V, et al . Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54:275–82. What is already known on this topic Persistence of attention

2015 Evidence-Based Mental Health

105. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. (Abstract)

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Symptoms of attention deficit hyperactivity disorder (ADHD), diagnosed mainly in children, often persist into adulthood. Adults in this group have a high rate of other psychiatric problems and functional difficulties in a number of key areas such as academic achievement, interpersonal relationships, and employment. Although the usefulness of immediate-release methylphenidate in children has been (...) calculated risk ratios (RRs) and 95% confidence intervals (CIs). For continuous outcomes, we calculated mean differences (MDs) or standardized mean differences (SMDs) with 95% CIs.Results from the 11 randomized controlled trials (474 participants, counting participants from cross-over studies as a single arm, and counting both arms from parallel studies) included in the review demonstrated improvement in core clinical ADHD symptoms of hyperactivity, impulsivity, and inattentiveness, and overall

2014 Cochrane

106. ADHD: medication and society

indexing assigned by CRD MeSH Attention Deficit Disorder with Hyperactivitys Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523 Email: info@gr.nl AccessionNumber 32014000924 Date abstract record published 23/07/2014 Health Technology Assessment (HTA) database Copyright © 2019 Health Council of the Netherlands (...) ADHD: medication and society ADHD: medication and society ADHD: medication and society Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. ADHD: medication and society. The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2014/19. 2014 Final publication URL Indexing Status Subject

2014 Health Technology Assessment (HTA) Database.

107. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. Full Text available with Trip Pro

Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. To investigate the association between drug treatment for attention-deficit/hyperactivity disorder (ADHD) and risk of concomitant suicidal behaviour among patients with ADHD.Register based longitudinal study using within patient design.Linkage of multiple national registers in Sweden.37,936 patients with ADHD born between 1960 and 1996 and followed from 2006 to 2009 for treatment status (...) by ADHD drug treatment and suicide related events (suicide attempt and completed suicide).Incidence rate of suicide related events during ADHD drug treatment periods compared with that during non-treatment periods.Among 37,936 patients with ADHD, 7019 suicide related events occurred during 150,721 person years of follow-up. At the population level, drug treatment of ADHD was associated with an increased rate of suicide related events (hazard ratio 1.31, 95% confidence interval 1.19 to 1.44). However

2014 BMJ

108. Management of ADHD in preschool-aged children

Management of ADHD in preschool-aged children Management of ADHD in preschool-aged children Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Management of ADHD in preschool-aged children View/ Open Date 2013-09 Format Metadata Abstract Behavior therapy interventions, such as parent training, are first-line treatment (...) for ADHD in preschool-aged children (three to five years of age). (Strength of Recommendation [SOR]: B, based on a systematic review of a small number of heterogeneous randomized controlled trials [RCTs].) Medication is an option for children with moderate to severe ADHD if behavior therapy has not been effective and if the benefits outweigh the harms. (SOR: B, based on a systematic review of a small number of heterogeneous RCTs.) Alternative therapies, such as elimination diets, have limited evidence

2014 Clinical Inquiries

109. Atomoxetine (Strattera) - adults with attention deficit hyperactivity disorder (ADHD)

Atomoxetine (Strattera) - adults with attention deficit hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - atomoxetine (Strattera) | | Appraisal information Search and reports atomoxetine (Strattera®) Reference No. 1361 Publication date: 27/02/2014 Last review date: 01/12/2016 Appraisal information atomoxetine (Strattera®) 10 mg capsule atomoxetine (Strattera®) 18 mg capsule atomoxetine (Strattera®) 25 mg capsule atomoxetine (Strattera®) 40 mg capsule atomoxetine (...) NHS Wales for the initiation of treatment in adults with attention deficit hyperactivity disorder (ADHD). Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria or the guidelines in International Classification of Mental and Behavioural Disorders (ICD). In adults, the presence of symptoms of ADHD

2014 All Wales Medicines Strategy Group

110. Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence

of this assessment has been made for the HTA database. Citation CADTH. Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions No conclusions can be drawn regarding the abuse potential of atomoxetine due to the limited data available. Misuse of methylphenidate and amphetamine-based ADHD drugs was found (...) Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence Abuse and misuse potential of drugs for attention deficit/hyperactivity disorder: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality

2014 Health Technology Assessment (HTA) Database.

111. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence

Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review (...) of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

2014 Health Technology Assessment (HTA) Database.

112. Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders

not associated with subsequent substance use disorders Paula D Riggs Statistics from Altmetric.com Commentary on: Humphreys KL , Eng T , Lee SS , et al . Stimulant medication and substance use outcomes: a meta-analysis . Context Attention deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders of childhood, affecting 3–7% of school-age children. 1 Stimulant medication is an effective treatment for childhood ADHD and is well established as a first-line treatment in most clinical (...) Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders Stimulant medication for ADHD not associated with subsequent substance use disorders | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2014 Evidence-Based Medicine

113. Guanfacine hydrochloride extended release (Intuniv XR ? Shire Canada Inc.) indication: attention deficit hyperactivity disorder

Guanfacine hydrochloride extended release (Intuniv XR ? Shire Canada Inc.) indication: attention deficit hyperactivity disorder Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder CADTH Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0349. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that guanfacine hydrochloride extended release (GXR) not be listed. Final

2014 Health Technology Assessment (HTA) Database.

114. Medication reduces crash risk among men with ADHD Full Text available with Trip Pro

implementation of skills and traits that include attending to the driving task, focusing on relevant hazards, and being aware of traffic and road conditions and responding appropriately. 1 Deficits in attention and impulse control put patients with attention-deficit hyperactivity disorder (ADHD) at increased crash risk. Consistent ADHD medication use, ensuring therapeutic levels while driving, has the potential to reduce this risk. 2 What does this paper add? This landmark population-based study is the first (...) Medication reduces crash risk among men with ADHD Medication reduces crash risk among men with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search

2014 Evidence-Based Mental Health

115. Atomoxetine is a second-line medication treatment option for ADHD

is already known on this topic? Atomoxetine is a non-stimulant that has no abusive potential and a presynaptic inhibitor of the norepinephrine transporter, and has been found to be a safe and effective treatment for attention deficit/hyperactivity disorder (ADHD) in children, adolescents and adults. 1 What this paper adds? This is the largest meta-analysis of randomised controlled trials of atomoxetine for ADHD. The effect size for atomoxetine versus placebo was higher for medication-naïve youth while (...) factors such as demographic factors, mean dose, etc, did not moderate the treatment response. Limitations Even though atomoxetine improved both inattentive and hyperactive symptoms, response was lower than for stimulants and 40% of participants taking atomoxetine had significant residual ADHD symptoms. Compared with placebo, a higher proportion of those taking atomoxetine had at least one adverse effect, experienced more weight loss and discontinued study participation. Important treatment response

2014 Evidence-Based Mental Health

116. Autism traits may be more prevalent in ADHD than previously reported

on this topic? Previous research has indicated that there are qualitative and quantitative differences in the behavioural phenotypes of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). 1 The presence of ASD traits in children with ADHD, however, generally portends a more severe profile of symptoms and impairments. Cooper and colleagues’ study is novel due to the very large sample size of children with ADHD, and because it assesses ASD traits on a continuous scale. What (...) Autism traits may be more prevalent in ADHD than previously reported Autism traits may be more prevalent in ADHD than previously reported | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password

2014 Evidence-Based Mental Health

117. Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence

medication for ADHD influences lifetime risk of substance use or dependence Statistics from Altmetric.com Question Question: Does exposure to stimulant medication for attention deficit hyperactivity disorder (ADHD) have an effect on the lifetime risk of substance use or dependence? Outcomes: Lifetime substance use or dependence (alcohol, cocaine, marijuana, nicotine and illicit non-specific drug). Method of assessing substance use/dependence is not reported for included studies. Methods Design (...) Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2014 Evidence-Based Mental Health

118. Review: recommendations for the assessment and management of sleep disorders in ADHD

Altmetric.com Question Question: What evidence-based or consensus-based recommendations can be made for the assessment and management of sleep problems in children and adolescents with attention deficit hyperactivity disorder (ADHD)? Outcomes: The assessment and management of sleeping problems are as reported. Methods Design: Systematic review. Data sources: PubMed, Ovid, EMBASE and Web of Knowledge were searched for peer-reviewed articles (study type not specified) published up to 31 October 2012. Study (...) Review: recommendations for the assessment and management of sleep disorders in ADHD Review: recommendations for the assessment and management of sleep disorders in ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers

2014 Evidence-Based Mental Health

119. Cognitive Behavioral Therapy for Attention Deficit Hyperactivity Disorder (Adults)

Cognitive Behavioral Therapy for Attention Deficit Hyperactivity Disorder (Adults) Cognitive Behavioral Therapy for adult ADHD – Society of Clinical Psychology Description Cognitive behavioral therapy (CBT) for adult ADHD provides concrete strategies and skills for coping with the core symptoms of ADHD (inattention, hyperactivity, impulsivity) and associated impairment in social, occupational, educational, and other domains. Components of CBT for ADHD include psychoeducation, training (...) in organization, planning, and time management, problem solving skills, techniques for reducing distractivity and increasing attention span, and cognitive restructuring particularly around situations that cause distress. Key References (in reverse chronological order) Emilsson, B., Gudjonsson, G., Sigurdsson, J.F., Baldursson, G., Einarsson, E., Olafsdottir, H., & Young, S. (2011). Cognitive behaviour therapy in medicationtreated adults with ADHD and persistent Symptoms: A randomized controlled trial. BMC

2014 Society of Clinical Psychology

120. Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD)

Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - lisdexamfetamine dimesylate (Elvanse) | | Appraisal information Search and reports lisdexamfetamine dimesylate (Elvanse®) Reference No. 188 Publication date: 03/12/2013 Last review date: 01/12/2016 Appraisal information lisdexamfetamine dimesylate (Elvanse®) 30 mg capsule lisdexamfetamine dimesylate (Elvanse®) 50 mg capsule lisdexamfetamine dimesylate (Elvanse® (...) programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision of a specialist in childhood and/or adolescent behavioural disorders. Final Appraisal Recommendation (FAR) Download AWMSG Secretariat Appraisal Report (ASAR) Download Clinical Expert (CE) Summary Download |

2013 All Wales Medicines Strategy Group